BioSpace News Archive

MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the initiation of a first-in-human clinical study to evaluate the pharmacokinetics and bioavailability of a new MN-166 (ibudilast) parenteral formulation.

Geron Corporation reported that it has granted non-statutory stock options to purchase an aggregate of 405,800 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

Astellas Pharma Inc. announced plans to create an integrated biotechnology campus in South San Francisco as its West Coast innovation and research center.

Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the Phase Ib study of Ascentage Pharma’s novel drug candidate, olverembatinib (HQP1351).

InnoCare (HKEX: 09969) today announced that tafasitamab (Minjuvi®) in combination with lenalidomide has been approved by the Health Commission and Medical Products Administration of Hainan Province, under the early access program in Boao Lecheng International Medical Tourism Pilot Zone, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT).

TIANGEN, a leading brand in the field of nucleic acid purification in China, has announced its participation in the 2022 American Association for Clinical Chemistry Annual Scientific Meeting & Clinical Lab Expo from July 26 to 28 in Chicago where it will be officially launching its brand in the US market.